FDA Needs More Time To Review GSK/Adolor’s Entereg
This article was originally published in The Pink Sheet Daily
Executive Summary
Adolor tells investors that FDA will not act on the postoperative ileus treatment in time to meet the May 10 PDUFA date.
You may also be interested in...
FDA Lets GSK/Adolor Resume Entereg Work
But regulatory hurdles could send GSK on its way, analysts say.
FDA Lets GSK/Adolor Resume Entereg Work
But regulatory hurdles could send GSK on its way, analysts say.
Adolor/GSK’s Entereg Approved By FDA
Cleared at last, hospital constipation drug brings risk management plan.